Faculty UTCI

Furhan Yunus, MD, FACP

UNDERGRADUTE EDUCATION:

1974-1979

Cadet College Hasan Abdal Pakistan High School
and College – Completed 1979

   
 

PROFESSIONAL EDUCATION:

1979 – 1983

University of Punjab
King Edward Medical College Pakistan - BS 8/83

 

1983 – 1985

University of Punjab
King Edward Medical College Pakistan
MBBS 12/85 (equivalent of MD) Completed 1985

 

POST GRADUATE TRAINING:

07/86 – 06/87

Internship: General Surgery & Medicine, Completed 6/87
Mayo Hospital, Lahore, Pakistan

   

07/87 – 04/88

Medical Officer at Mayo Hospital
Lahore, Pakistan

   

04/88 – 06/90

Relocated to the United States – took USMLE
and FLEX Exams – applied for residencies

   

7/90 – 6/91

Internship: Internal Medicine, Completed 6/91
Methodist Hospital, Memphis, TN

   

7/91 – 6/93

Residency: Internal Medicine, Completed 6/93
Methodist Hospital, Memphis, TN

   

7/93 – 6/95

Fellowship: Oncology-Hematology, Completed 6/95
Arizona Cancer Center University of Arizona, Tucson, AZ


HONORS:

Elonor B. Connel Fellow 1994 - 1995
Outstanding Fellowship in Hematology - Oncology
Chief Fellow, Arizona Cancer Center 1994 - 1995
Academic Merit Scholar, King Edward Medical College
Fellowship in the American College of Physicians
Castle Connolly Medical Best Doctor in America 2006 & 2009
Nominated Health Care Hero 2007 & 2008

 

BOARD CERTIFICATION:

1989

FLEX

1988

FMGEMS

 

LICENSURE:

Date Issued

Status

Expiration Date

Tennessee - #MD26582

5/18/1995

Active

10/31/11

Mississippi - #15052

9/9/1996

Active

6/30/12

 

BOARD CERTIFIED: Medical Oncology


SOCIETY MEMBERSHIPS:

Memphis and Shelby County Medical Society

Desoto County Medical Society

Tennessee Medical Association (TMA)

American Medical Association (AMA)

American College of Physicians (ACP)

American Society of Internal Medicine (ASIM)

American Society of Clinical Oncology (ASCO)

American Society of Hematology (ASH)

Association of Pakistani Physicians of North America (APPNA)

American Society of Blood and Marrow Transplantation (ASBMT)

 
 

PRACTICE APPOINTMENTS:

01/01/10 – present

Associate Chief Medical Director
University of Tennessee Cancer Institute

   

05/01/08 – present

Interim Chief, Division of Hematology Oncology
University of Tennessee Health Science Center

   

07/01/08 – present

Associate Professor of Medicine
University of Tennessee Health Science Center

   

07/91/00 – present

Blood and Marrow Transplant Center of the Mid-South
Program Director
Affiliate of Methodist Healthcare/UTCI
1265 Union Avenue
Memphis, TN 38104

   

07/01/08 – 06/30/10

Fellowship Program Director
University of Tennessee Health Science Center

   

04/01/01 – 12/31/09

Chief Medical Officer
University of Tennessee Cancer Institute
1331 Union Ave., Suite 800
Memphis, TN 38104

   

07/01/01 – 06/30/08

Assistant Professor
University of Tennessee, Memphis

   

11/99 – 06/00

Medical Director
Methodist Hospital Bone Marrow Transplant Program
1265 Union Avenue
Memphis, TN 38104

   

09/96 – 4/1/01

The Boston Cancer Group, PLC
1331 Union Avenue, Ste. 800
Memphis, TN 38104

   

07/95 – 08/96

Cancer Specialty Clinic, P.C.
1325 Eastmoreland, Ste. 370
Memphis, TN 38104

 

TEACHING EXPERIENCE: Details available upon request


COMMITTEE PARTICIPATION:

Hematology Oncology Training Program Committee
National Comprehensive Cancer Network (NCCN) Board of Directors
National Comprehensive Cancer Network CML Guidelines Panel
National Comprehensive Cancer Network Guidelines Steering Committee
National Comprehensive Cancer Network Myeloma Guidelines Panel
United Healthcare Oncology Physician Advisory Board Member
Blue Cross / Blue Shield of Tennessee Technology Advisory Board Member
University of Tennessee Cancer Institute Steering Committee
Methodist University Hospital Senior Leadership Council


HOSPITAL / CLINICAL APPOINTMENTS:

Provider at all Adult Hospitals in the Mid-South.
Detailed List Available Upon Request


PRESENTATIONS:
Detailed List Available Upon Request


ABSTRACTS:

    1. Feasibility and efficacy of neoadjuvant sunitinib before nphon-sparing surgery. Silberstein JL, Millard F. Mehrazin R, Kopp R, Bazzi W, Diblasio CJ, Patterson AL, Downs TM, Yunus F, Kane CJ, Derweesh IH. BJU Int. 2010 Apr 15.

 

    1. Effect of race and comorbidities on patterns of bevacizumab toxicity: A single-institution experience. Raza, M, Yunus F, et. al. Abst #6131, 2010 ASCO Annual Meeting.

 

    1. Retrospective review of neoadjuvant sunitinib in renal cell carcinoma (RCC). Millard FE, Silberstein J, Kopp R, Yunus F, et.al. 2010 ASCO Annual Meeting.

 

    1. The Impact of Telemedicine in Cancer Care. F. Yunus, S. Gray, KC Fox, JW Allen, J. Sachdev, M. Merkel, B. Chambley, T. Waters. 2009 ASCO Annual Meeting. Abstract # e20508.

 

    1. Technology Exchange for Cancer Health Network. F. Yunus, T. Waters, M. Jahanzeb, F. K. Fox, S. Minhas, R. Yunus, P, Sydow, M. Merkel, R. Kersey, K. Gray. American Society of Clinical Oncology; June 20, 2007; 19598

 

    1. Incidence and Risk Factors of Bisphosphonate Associated Osteonecrosis of the Jaws. M. Stumpe, R. Chandrs, F. Yunus, S. Samant. American Society of Clinical Oncology Meeting Abstracts; June, 20, 2007: 9074

 

    1. Adjuvant Trastuzumab (T) Therapy in HER2 + Breast Cancer After ASCO 2005: Patients’ Attitudes and Immediate Economic Burden. S.M. Benn, G. Jha, T.W. Ratliff, K. Spiers, R. Baskin, F. Yunus, R. Osarogiagbon, B. Boston, S. Minhas, M. Jahanzeb. ASCO Meeting Abstracts, June 20, 2006: 10565.

 

    1. Safety and Efficacy of Pentostatin and Rituximab in Patients with Low-Grade B-Cell Non-hokgkin’s Lymphoma, Including Chronic Lymphocytic Leukemia (Protocol N007). R.R. Mena, J. Smith, S. George, G. Geils, F. Yunus. ASCO Meeting Abstract, July 15, 2005: 6569

 

    1. “African American and Caucasians With Myeloma Have Similar Outcomes in the Current ERA: A Tumor Registry Study. McClune B, Kumar B, Buadi F, Womeodu R, Wright K, Baskin R, Minhas S, Ratliff T, Spiers K, Yunus F, Przepiorka D. Malignant Hematology and Transplantation, UT Cancer Institute, Memphis, TN; Center on Health Disparities, University of Tennessee, Memphis, TN; Tumor Registry, Methodist Healthcare, Memphis, TN. American Society of Hematology, December 2004

 

    1. “Race Has No Effect On Survival in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. Buadi F, McClune B, Moore Y, Womeodu R, Yunus F, Walsh W, Minhas S, Przepiorka D. Malignant Hematology and Transplantation, UT Cancer Institute, Memphis, TN; Center on Health Disparities, University of Tennessee, Memphis, TN. American Society of Hematology, December 2004

 

    1. “Phase II Study of Fludarabine Phosphate and Mitoxantrone Followed by Anti-CD20 Monoclonal Antibody in the Treatment of Patients with Newly Diagnosed, Advanced Low Grade Non-Hodgkin’s Lymphoma (LGNHL): Interim Results. Gregory SA, Venugopal P, Adler S, O’Brien TM, Porter CP, Yunus F, Robin EL; Rush-Presbyterian-St. Luke’s Medical Center/Rush University, Chicago, IL; University of Tennessee Cancer Institute, Memphis, TN; Munster Community Hospital, Munster IN. American Society of Hematology, Abstract #1499, December 2003

 

    1. “Phase II Multicenter Trial of Pentostatin and Rituximab in Patients With Previously Treated and Untreated Non-Hodgkin’s Lymphoma (NHL). Yunus F, George S, Smith J, Geils Sr G, Geils Jr G, University of Tennessee Cancer Institute , Memphis, TN; Cancer & Blood Institute of the Desert, Rancho Mirage, CA; Charleston Hematology Oncology, Charleston, SC. American Society of Hematology, Abstract #2373, December 2003

 

    1. “Megace and Thrombosis in Cancer Patients." Kumar B, Raza A, Yunus F; University of Tennessee Cancer Institute, Memphis, TN. American Society of Hematology, Abstract #4185, December 2003

 

    1. ”Chemoimmunotherapy with Combination of Rituximab, GMCSF, and CHOP in Patients With Previously Untreated Aggressive Non-Hodgkin’s Lymphoma. Venugopal P, Wooldridge J, Yunus F, Adler SS, Shammo JM, Enschede SH, O’Brien TM, Means A, Nathan S, Venugopal G, Sokolovsky TB, Gregory SA; Rush Presbyterian-St. Luke’s Medical Center, Chicago, IL; University of Iowa, Iowa City, IA; University of Tennessee Cancer Institute, Memphis, TN; Cook County Hospital, Chicago IL. American Society of Hematology, Abstract #4930, December 2003

 

    1. “Phase II Multicenter Trial of Pentostatin and Rituximab in Patients With Previously Treated and Untreated Chronic Lymphocytic Leukemia (CLL). Yunus F, George S, Smith J, Geils Sr G, Geils Jr G; University of Tennessee Cancer Institute, Memphis, TN; Cancer & Blood Institute of the Desert, Rancho Mirage, CA; Charleston Hematology Oncology, Charleston, SC. American Society of Hematology, Abstract #5168, December 2003

 

    1. “Combined Fludarabine, Mitoxantrone, and Rituximab Achieves a High Response As Initial Treatment For Advanced Low Grade Non-Hodgkin’s Lymphoma (LGNHL). Gregory SA, Venugopal P, Adler S, Enschede S, Yunus, F, O’Brien TM, O’Donnell DF, Robin EL; Rush Presbyterian-St. Luke’s Medical Center, Chicago, IL; Boston Baskin Cancer Group, Memphis, TN; Community Hospital of Munster, Munster IN. American Society of Hematology, Abstract #1401, December 2002

 

    1. “Phase II Study of Rituximab in Combination With CHOP Chemotherapy and GMCSF in Patients With Previously Untreated Aggressive Non-Hodgkin’s Lymphoma. Venugopal P, Gregory SA, Wooldridge J, Yunus F, Adler S, Shammo J, Enschede S, O’Brien T, Franson P, Porter C; Rush Presbyterian-St. Luke’s Medical Center, Chicago, IL; University of Missouri, MO; University of Tennessee, Memphis, TN. American Society of Hematology, Abstract #4798, December 2002

 

    1. “Encouraging Survival Results With RSR13 and Concurrent Radiation Therapy: Interim Analysis of a Phase II Study For Locally Advanced Unresectable Non-Small Cell Lung Cancer. Nabid A, Choy H, Stea B, Roa W, Souhami L, Yunus F, Fortier M; Centre hospitalier Universitaire de Sherbrooke, Sherbrooke, PQ Canada; Vanderbilt University Medical Center, Nashville, TN; University of Arizona Health Science Center, Tucson, AZ; Cross Cancer Inst., Edmonton, AB Canada; Montreal General Hospital, Montreal PQ Canada; Boston Baskin Cancer Group, Memphis, TN. American Society of Clinical Oncology, Abstract #1236, 2002

 

    1. “Phase II Study of the Farnesyl Transferase Inhibitor (FTI) R11577 (Zarnestra) In Patients With Relapsed Small Cell Lung Cancer (SCLC). Heymach JV, De Porre PM, De Vore III RF, Johnson DH, Khuri FR, Richards HM, Safran H, Schlabach LL, Yunus F, Jia X, Belgium BE; Vanderbilt Ingram CC/VICCAC, Nashville, TN; MD Anderson Cancer Center, Houston, TX; Janssen Research Foundation, Titusville, NJ; Brown University, Providence, RI; Erlanger HS/VICCAN, Chattanooga, TN; Boston Baskin Cancer Group, Memphis, TN. American Society of Clinical Oncology, Abstract #1275, 2002

 

    1. “Multicenter Phase II Trial of Weekly Navelbine Plus Herceptin in Chemonaive Patients With Her2 Positive Metastatic Breast Carcinoma”. Jahanzeb M, Mortimer J, Yunus F, Irwin D, Speyer J, Koletsky A, Klein P, Kronish L, Sabir T; Salick Healthcare Inc., Boca Raton, FL; Washington University, St. Louis, MO; Boston Cancer Group, Memphis, TN; Salick Healthcare Inc., Berkley CA; Salick Healthcare Inc., New York, NY. American Society of Clinical Oncology, Abstract #1986, 2001

 

    1. A Phase II Study of Paclitaxel, Carboplatin, and Hyperfractionated Radiation Therapy for Locally Advanced Inoperable Non-Small Cell Lung Cancer (A Vanderbilt Cancer Center Affiliate Network Study)Choy Hak, Devore, Russell; Hande, Kenneth; Porter, Lester; Rosenblatt, Paul; Yunus, F.; Schlaback, Larry; Smith, Clyde; Shyr, Yu; Johnson, David H Seminar in Oncology 2000 Jul 01

 

    1. “Zoledronate Acid Superior to Pamidronate in the Treatment of Tumor-Induced Hypercalcemia: A Pooled Analysis” P.Major, A.Lortholary, J.Hon, E.Abdi, G.Mills, H.Meussen, F.Yunus, R.Bell, E.Quebe-Fehling and J.Seaman For The Zoledronic Acid TIH Study Group. Journal of Clinical Oncology, Jan. 15, 2001: 558-567

 

    1. “Zoledronic Acid Is Superior To Pamidronate in the Treatment of Tumor-Induced Hypercalcemia: A Pooled Analysis. Major P, Lortholary A, Hon J, Abdi E, Mills G, Meussen H, Yunus F, Bell R, Body JJ, Quebe-Fehling E, Seaman J. American Society of Clinical Oncology, Abstract #2382, 2000

 

    1. “Phase I Trial of Outpatient Weekly Irinotecan (CPT-11) and Carboplatin With Concurrent Radiation Therapy For Stage III Unresectable Non-Small Cell Lung Cancer: A Vanderbilt Cancer Center Affiliate Network (VCCAN) Trial. Chakravarthy A, Choy H, DeVore R, Roberts J, Yunus F, Jagasia M, Laporte K, Hande K, Johnson D. American Society of Clinical Oncology, Abstract #2040, 2000

 

    1. “Phase I Trial of Outpatient Irinotecan and Concurrent Radiation Therapy for Stage III Unresectable Non-Small Call Lung Cancer: A Vanderbilt Cancer Center Affiliate Network (VCCAN) Trial. Anuradha Chakravarthy, Hak Choy, Russell F. DeVore, John R. Roberts, Furhan Yunus, Madan Jagasia, Kazel L. LaPorte, Kenneth R. Handle, David H. Johnson, Methodist Hospital , Memphis, TN American Society of Clinical Oncology Volume 18; 1924:498a. 1999

 

    1. “Preliminary Results of a Multicenter Phase II Trial of Weekly Cisplatin (CDDP) and Irinotecan (CPT-11) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Vanderbilt Cancer Center Affiliate Network Study.” M. Jagasia, C. Langer, F. Yunus, J. Rogers, R. Lamar, L. Schalabach, D. Johnson, P. Krozely, N. McCullough, Y. Shyr, D. Carbone, R. DeVore, Vanderbilt University Cancer Center, Nashville, TN. Fox Chase Center, Philadelphia, PA. Methodist Health Systems, Memphis, TN. West Virginia University, Morgantown, WV. Saint Thomas Hospital, Nashville, TN. Erlanger Medical Center, Chattanooga, TN. American Society of Clinical Oncology Volume 18; 1967:510a. 1999

 

    1. “Preliminary Analysis of a Phase II Study of Paclitaxel, Carboplatin, and Hyperfractionated Radiation Therapy For Locally Advanced Inoperable Non-Small Cell Lung Cancer.” Choy H; DeVore RF 3rd; Hande KR; Porter LL; Rosenblatt P; Yunus F; Schlabach L; Smith C; Shyr Y; LaPorte K; Johnson DH; Radiation Department, Vanderbilt University Medical Center

 

    1. Seminar in Oncology 1997 Aug;24(4 Suppl 12):S12-21-S12-26.

 

 

PUBLICATIONS:

    1. Non-Hodgkin’s Lymphomas. Zelenetz AD, Abramson JS, Advani RH, Amdreados CB, Byrd JC, Czuczman MS, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminski MS, Kim YH, Lacasce AS, Mughal TI, Nademanee A, Porcu P, Press O, Prosnitz L, Reddy N, Smith MR, Sokol L, Swinnen L, Vose JM, Wierda WG, Yahalom J, Yunus F. J Natl Comr Canc Netw. 2010 Mar; 8(3):288-334.

 

    1. Multiple Myeloma. Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Gasparetto C, Huff CA, Jagasia M, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Tricot G, Vose JM, Weber D, Yahalom J, Yunus F. J Natl Compr Canc Netw. 2009 Oct;7(9):908-42.

 

    1. “Incidence and risk factors of bisphosphonate associated osteonecrosis of the jaws.” Stumpe MR, Chandra RK, Yunus F, Samant S. Head & Neck, 2009 Feb; 31(2):202-206.

 

    1. Non-Hodgkin’s Lymphomas. Zelenetz AD, Advani RH, Byrd JC, Czuczman MS, Damon LE, Duvic M, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminski MS, Kim YH, Lacasce AS, Nademanee A, Oseen EA, Porcu P, Press O, Prosnitz L, Smith MR, Sotomayor EM, Vose JM, Yahalom J, Yunus F. J Natl Comr Canc Netw. 2008 Apr; 6(4):356-421.

 

    1. Multiple Myeloma: Clinical Practice Guidelines in Oncology. Anderson KC, Alsina M, Bensiger W, Biermann JS, Chanan-Khan A, Comenzo RL, De Castro CM, Djulbegovic B, Farag S, Huff CA, Meredith R, Schriber J, Shrieve D, Singhal S, Smith MR, Stofckerl-Goldstein K, Vose JM, Weber D, Yahalom J, Yunus F. J Natl Compr Canc Netw. 2007 Feb; 5(2):118-47.

 

    1. A Phase III, Double-Blind, Randomized Trial of Palonosetron Compared with Ondansetron in Preventing Chemotherapy-Induced Nausea and Vomiting Following Highly Emetogenic Chemotherapy”. Aapo, M.S., Grunberg, S.M., Manikhas, G.M., Olivares, G., Suarez, T., Tjulandin, S.A., Bertoli, L. F., Yunus, F., Morica, B., Lordick, F., and Macciocchi, A.; Annals of Oncology, Sept. 2006; Volume 17 No. 9 pages 1441- 1449.

 

    1. “Survival Non-Inferiority of a Non-Platinum Combination Compared to Platinum Based Chemotherapy as Initial Therapy for Advanced Non-Small Cell Lung Cancer”. JCO; July 2004, volume 22, 14s

 

    1. “Fixed-Dose PegfilgrastimmIs Safe and Allows Neutrophil Recovery In Patients With Non-Hodgkin’s Lymphoma”. George S, Yunus F, Case D, Yang BB, Hackett J, Shogan JE, Meza LA, Neumann TA, Liang BC; Cancer & Blood Institute of the Desert, Rancho Mirage, CA. Leuk Lymphoma 44(10): 1691-6, October 2003

 

    1. “Phase II Trial of Weekly Vinorelbine and Trastuzumab As First Line Therapy In Patients With Her2 (+), Metastatic Breast Cancer”. Jahanzeb M, Mortimer J, Yunus F, Irwin D, Speyer J, Koletsky A, Klein P, Sabir T, Kronish L; The Boca Raton Comprehensive Cancer Center, Florida. Oncologist 7(5): 410-17, 2002

 

    1. “Irinotecan Plus Gemcitabine Induces Both Radiographic and CA 19-9 Tumor Marker Responses In Patients With Previously Untreated Advanced Pancreatic Cancer”. Rocha Lina CM, Savarese D, Bruckner H, Dubek A, Eckardt J, Hainsworth J, Yunus F, Lester E, Miller W, Saville W, Elfring GL, Locker PK, Compton LD, Miller L, Green MR; H. Lee Moffitt Cancer Center, University of South Florida, Gastrointestinal Program Office, Tampa FL. Clinical Oncology 20(5): 1182-91, March 2002

 

    1. “A Phase II Study of Paclitaxel, Carboplatin, and Hyperfractionated Radiation Therapy For Locally Advanced Inoperable Non-Small Cell Lung Cancer (A Vanderbilt Cancer Center Affiliate Network Study).” H Choy, RF DeVore, KR Hande, LL Porter, P Rosenblatt, F Yunus, L Schlabach, C Smith, Y Shyr, D Johnson. Int J Radiat Oncol Biol Phys 2000;47(4):931-937

 

    1. “Irinotecan Plus Fluorouracil and Leucovorin For Metastatic Colorectal Cancer”. LB Saltz, et all. New England Journal of Medicine, 2000, Volume 13; pg. 905-914.

 

 

CLINICAL TRIALS, Principal Investigator:

    • Protocol Number 109493: A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resectable MAGE-A3-positive non-small cell lung cancer.
      February, 2010 – Present Role: Sub-Investigator

 

    • CALGB 10603 (NOVARTIS CPKC412A2301): A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND # 101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age with FLT3 Mutated Acute Myeloid Leukemia (AML)
      February, 2010 – Present Role: Sub-Investigator

 

    • PCYC-1001: Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment with Gemcitabine
      January, 2010 – Present Role: Sub-Investigator

 

    • Protocol HN0209: A Phase I/II Trial of the Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
      December 2009 – Present Role: Sub-Investigator

 

    • Protocol CA180227: A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined with Dasatinib to Docetaxel Combined with Placebo in Castration-Resistant Prostate Cancer
      October, 2009 – Present Role: Sub-Investigator

 

    • INCB 18424-351: A Randomized, Double-blind, Placebo-controlled Study of the JAK Inhibitor INCB018424 Tablets Administered Orally to Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia Myelofibrosis (PET-MF)
      September 2009 - Present Role: Principal Investigator

 

    • Protocol Number: CVX-060-102: A Phase IB/II Multicenter Trial of CVX-060, a Selective Angiopoietin-2 (ANG-2) Binding, Anti-Angiogenic CovX-Body, in Combination with Sunitinib in Patients with Advanced Renal Cell Carcinoma
      August 2009 – Present Role: Sub-Investigator

 

    • Protocol CC-5013-MCL-001: A Phase 2, Multicenter, Single-Arm, Open-Label Study To Determine The Efficacy And Safety of Single-Agent Lenalidomide (Revlimid®) In Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment with Bortezomib or are Refractory to bortezomib, The "EMERGE" trial.
      August, 2009 – Present Role: Principal Investigator

 

    • Protocol Number : CRAD001Y 2301: "A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination with Exemestane in the Treatment of Postmenopausal Women with Estrogen Receptor Positive, Locally Advanced or Metastatic Breast Cancer who are refractory to Letrozole or Anastrozole"
      August, 2009 - Present Role: Sub-Investigator

 

    • Protocol No: RAD001 L2202: Novartis Pharmaceuticals trial entitled: An open-label, multicenter phase II study to compare the efficacy and safety of RAD001 as first-line followed by second-line sunitinib versus sunitinib as first-line followed by second-line RAD001 in the treatment of patients with metastatic renal cell carcinoma
      August, 2009 - Present Role: Sub-Investigator

 

    • Protocol 3066K1-2247: A Phase II Study of Temsirolimus as 2nd line Therapy in Patients with Advanced, Unresectable Hepatocellular Carcinoma
      August 2009 – Present Role: Sub-Investigator

 

    • Protocol Number: S0802: A Randomized Phase II Trial of Weekly Topotecan with and without AVE0005 (Aflibercept; NSC-724770) in Patients with Platinum Treated Extensive Stage Small Cell Lung Cancer (E-SCLC)
      August 2009 – Present Role: Sub-Investigator

 

    • Protocol CA196005: A Randomized Double-Blinded Phase II Study of Carboplatin/Paclitaxel/CT-322 versus Carboplatin/Paclitaxel /Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer with Non Squamous Histology
      July, 2009 – Present Role: Sub-Investigator

 

    • Protocol Number: 111482: A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma
      April 2009 – Present Role: Sub-Investigator

 

    • Protocol Number: N/A : Neoadjuvant Weekly nab-paclitaxel (Abraxane®) Plus Carboplatin Followed by Doxorubicin Plus Cyclophosphamide with Bevacizumab Added Concurrently to Chemotherapy for Palpable and Operable Triple Negative Invasive Breast Cancer (phase 2)
      October 2008 – Present Role: Sub-Investigator

 

    • Protocol Number: 3144A2-3003-WW: A Phase 3, Randomized, Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine for the Treatment of ErbB-2-Positive Locally Advanced or Metastatic Breast Cancer
      March 2009 – Present Role: Sub-Investigator

 

    • Protocol Number: HYT111127: An Open-Label, Multicenter, Non-comparative, Phase II Study of Oral Topotecan in Combination with Bevacizumab for Second-line Treatment in Subjects with Relapsed Small-Cell Lung Cancer (SCLC)
      September 2008 – Present Role: Sub-Investigator

 

    • Protocol Number: MED-PO2-06005: A Phase II Randomized Study of Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer
      August 2008 – Present Role: Principal Investigator

 

    • Protocol number: CAMN107AUS09: A multi-center, open-label, exploratory study of Bcr-Abl kinetics in adult patients on nilotinib with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP) and a suboptimal molecular response to imatinib (phase 2)
      July 2008 – Present Role: Principal Investigator

 

    • Protocol Number: H6Q-MC-S028: An Open-label, Randomized, Phase 2 Study of R-CHOP Plus Enzastaurin versus R-CHOP in the First-Line Treatment of Patients with Intermediate and High-Risk Diffuse Large B-Cell Lymphoma
      May 2008 – Present Role: Principal Investigator

 

    • Protocol Number: CP02-0452
      Randomized Phase III Study of Docetaxel or Pemetrexed with or without Cetuximab in Patients with Recurrent or Progressive Non-Small Cell Lung Cancer after Platinum-Based Therapy
      April, 2008 – Present Role: Sub-Investigator

 

    • CIRG (TRIO) 011/NSABP B-44-I /ROCHE BO20906 (BETH) ('Study'): Study Title: A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2 Positive Node Positive or High Risk Node Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab
      April, 2008 – Present Role: Sub-Investigator

 

    • Protocol Number: 20050236: A Randomized, Open-Label, Controlled, Phase II Trial of Combination Chemotherapy with or without Panitumumab as First-line Treatment of Subjects with Metastatic or Recurrent Head and Neck Cancer, and Cross-over Second-line Panitumumab Monotherapy of Subjects who Fail the Combination Chemotherapy Only Arm
      December 2007 – Present Role: Principal Investigator

 

    • SWOG S0600: Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC-714692) or Bevacizumab (NSC-704865) as Second-Line Therapy for Patients with Metastatic Colorectal Cancer who have Progressed on Bevacizumab with Either FOLFOX, OPTIMOX or XELOX
      October 2007 – Present Role: Sub-Investigator

 

    • Protocol Number: OSI3602s: Multicenter Randomized Phase II Study of Erlotinib, Cisplatin and Radiotherapy versus Cisplatin and Radiotherapy in Patients with Stage III and IV Squamous Cell Carcinoma of the Head and Neck
      September 2007 – Present Role: Principal Investigator

 

  • Protocol Number: OSI-774-302: A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (erlotinib) Following Complete Tumor Resection with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-small Cell Lung Carcinoma who have EGFR-positive Tumors
    June 2007 – Present Role: Sub-Investigator